Anti-integrin αvβ6 antibody in Takayasu arteritis patients with or without ulcerative colitis.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 17 02 2024
accepted: 05 04 2024
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 24 5 2024
Statut: epublish

Résumé

It has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. A total of 227 Japanese TAK patients were recruited in the current study and their serum samples were subjected to measurement of anti-integrin αvβ6 Ab by ELISA. The clinical information, including the co-occurrence of UC, was collected. The HLA allele carrier status was determined by Luminex or genotype imputation. The information about the presence of UC was available for 165 patients, among which eight (4.84%) patients had UC. Anti-integrin αvβ6 antibody was identified in 7 out of 8 TAK subjects with UC (87.5%) while only 5 out of 157 (3.18%) TAK subjects without UC had the antibody (OR 121, p=7.46×10 The prevalence of anti-integrin αvβ6 Ab was high in TAK patients with UC, but not in the absence of concomitant UC. The effect of

Sections du résumé

Background UNASSIGNED
It has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients.
Methods UNASSIGNED
A total of 227 Japanese TAK patients were recruited in the current study and their serum samples were subjected to measurement of anti-integrin αvβ6 Ab by ELISA. The clinical information, including the co-occurrence of UC, was collected. The HLA allele carrier status was determined by Luminex or genotype imputation.
Results UNASSIGNED
The information about the presence of UC was available for 165 patients, among which eight (4.84%) patients had UC. Anti-integrin αvβ6 antibody was identified in 7 out of 8 TAK subjects with UC (87.5%) while only 5 out of 157 (3.18%) TAK subjects without UC had the antibody (OR 121, p=7.46×10
Conclusions UNASSIGNED
The prevalence of anti-integrin αvβ6 Ab was high in TAK patients with UC, but not in the absence of concomitant UC. The effect of

Identifiants

pubmed: 38784377
doi: 10.3389/fimmu.2024.1387516
pmc: PMC11111853
doi:

Substances chimiques

Integrins 0
integrin alphavbeta6 0
Antigens, Neoplasm 0
HLA-B52 Antigen 0
Autoantibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1387516

Informations de copyright

Copyright © 2024 Ishikawa, Yoshida, Yoshifuji, Ohmura, Origuchi, Ishii, Mimori, Morinobu, Shiokawa and Terao.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Yuki Ishikawa (Y)

Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.

Hiroyuki Yoshida (H)

Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Gastroenterology, Kansai Electric Power Hospital, Osaka, Japan.

Hajime Yoshifuji (H)

Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Koichiro Ohmura (K)

Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Rheumatology, Kobe City Medical Center General Hospital, Kobe, Japan.

Tomoki Origuchi (T)

Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Tomonori Ishii (T)

Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan.

Tsuneyo Mimori (T)

Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Rheumatology, Ijinkai Takeada General Hospital, Kyoto, Japan.

Akio Morinobu (A)

Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Masahiro Shiokawa (M)

Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Chikashi Terao (C)

Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan.
The Department of Applied Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH